MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (MPGN)
Clinical trials for MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (MPGN) explained in plain language.
Never miss a new study
Get alerted when new MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (MPGN) trials appear
Sign up with your email to follow new studies for MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (MPGN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare kidney patients: pegcetacoplan early access program opens
Disease control APPROVED_FOR_MARKETINGThis program offers early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that cause protein in the urine and active kidney damage. Participants must have a confirmed diagnosis and limited response to other trea…
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (MPGN)
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
New hope for rare kidney patients: long-term drug trial shows promise
Disease control OngoingThis study looks at the long-term safety and effectiveness of a drug called pegcetacoplan for people with two rare kidney diseases: C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN). About 100 adults who already completed a one-year stu…
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (MPGN)
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC